<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619136</url>
  </required_header>
  <id_info>
    <org_study_id>MP-10-2016-2619</org_study_id>
    <nct_id>NCT02619136</nct_id>
  </id_info>
  <brief_title>Myocardial Ischemia and Transfusion</brief_title>
  <acronym>MINT</acronym>
  <official_title>Myocardial Ischemia and Transfusion: A Pilot, Multi-centre, Open-label Randomized Controlled Trial of Two Commonly Used Transfusion Strategies in Patients With Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Blood Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MINT: A pilot, multi-centre, open-label randomized controlled trial of two commonly used&#xD;
      transfusion strategies in patients with myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart attacks are conditions where blood flow to the heart muscle is dangerously low -&#xD;
      eventually causing heart muscle to die. Drugs improving the blood flow, and procedures such&#xD;
      angioplasty, are the mainstay of therapies. They will only work if there is enough oxygen&#xD;
      transported in blood. In fact, the heart may be deprived of oxygen not only because of the&#xD;
      heart attack itself but also because of low blood counts (or anemia). Anemia, or low blood&#xD;
      counts, may be caused by bleeding or by conditions such as cancer, kidney failure, chronic&#xD;
      infections or conditions such as severe arthritis. A transfusion increases the delivery of&#xD;
      oxygen to the heart muscle. However, we do not know at what level of anemia to initiate blood&#xD;
      transfusion to prevent permanent heart damage. Indeed, having low blood counts may be harmful&#xD;
      but blood transfusions also carries important risks including extra fluid in the lungs and&#xD;
      heart inability to pump effectively.&#xD;
&#xD;
      In previous studies, we demonstrated that giving less blood is safer in most patients. But,&#xD;
      there is little evidence in patients with heart attack. This first pilot trial aims to make&#xD;
      sure that a large study that will answer the question is doable. The large trial aims to&#xD;
      determine when and how much blood to give to minimize damage. In both studies, we will divide&#xD;
      patients who have a heart attack into two groups in the hopes of preventing patients from&#xD;
      dying. One group will receive more blood and the other group less blood. In the pilot trial,&#xD;
      we will evaluate if we can recruit patients with heart attack in a timely fashion. This trial&#xD;
      will span over 12 months. If patient recruitment goes well, we will move ahead with the&#xD;
      second phase of the project involving over 3500 patients. We plan to record the numbers of&#xD;
      patients who die or have another heart attack as well as if doctors follow treatment plans.&#xD;
      The 5-year large scale project will provide a definitive answer to the amount and optimal&#xD;
      timing of blood transfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment rate</measure>
    <time_frame>Time Frame: 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent non-fatal myocardial infarction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Restrictive Transfusion Strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal Transfusion Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transfusion</intervention_name>
    <description>Red Blood Cell Transfusion</description>
    <arm_group_label>Liberal Transfusion Strategy</arm_group_label>
    <arm_group_label>Restrictive Transfusion Strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients with hemoglobin level less than 100 g/L who present with an&#xD;
             ST-segment Elevation Myocardial Infarction (STEMI), or Non-ST-Elevation Myocardial&#xD;
             Infarction (NSTEMI);&#xD;
&#xD;
          -  Definitive evidence of myocardial necrosis, and patients will have at least one of the&#xD;
             following:&#xD;
&#xD;
               1. symptoms of ischemia;&#xD;
&#xD;
               2. new/presumed new ST segment-T wave (ST-T) changes or new left bundle branch block&#xD;
                  (LBBB);&#xD;
&#xD;
               3. development of pathological Q waves;&#xD;
&#xD;
               4. imaging evidence of new loss of viable myocardium or new regional wall motion&#xD;
                  abnormality; and/or&#xD;
&#xD;
               5. identification of an intracoronary thrombus by angiography.&#xD;
&#xD;
          -  Type I and Type II myocardial infarction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled acute bleeding at the time of randomization defined as the need for&#xD;
             uncrossed or non-type specific blood;&#xD;
&#xD;
          -  Decline blood transfusion;&#xD;
&#xD;
          -  Planned for cardiac surgery within 30 days;&#xD;
&#xD;
          -  Considered brain dead;&#xD;
&#xD;
          -  Have been deemed palliative by their treatment team (no commitment to aggressive&#xD;
             on-going care);&#xD;
&#xD;
          -  With inability to cross match blood;&#xD;
&#xD;
          -  No contact information to assure post-discharge follow-up;&#xD;
&#xD;
          -  Cardiogenic shock.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hébert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Hébert, MD</last_name>
    <phone>5148908000</phone>
    <email>paul.hebert.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romain Rigal, PharmD, MSc</last_name>
    <phone>5142134692</phone>
    <email>romain.rigal.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

